Steroid use linked to higher complication risks and healthcare costs in MG
Glucocorticoids are a cornerstone of MG treatment, but prolonged use can lead to complications and higher healthcare costs.
News
-
-
New research provides insights on safe treatment discontinuation in MG
Researchers identified four factors that may predict the risk of relapse after treatment discontinuation in patients with myasthenia gravis.
-
Efgartigimod found safe, effective in small-scale study of children with MG
A retrospective analysis of 17 children with juvenile MG in China supports the safety and efficacy of efgartigimod.
-
Higher body weight may raise risk of MG, study finds
A large national study from Korea found an association between higher BMI and risk of developing myasthenia gravis.
-
Study reveals higher cancer risk in myasthenia gravis
People with myasthenia gravis had higher rates of cancer both before and after diagnosis compared with matched controls.
-
Claseprubart quickly improves symptoms in myasthenia gravis trial
Claseprubart produced rapid and meaningful improvements in daily function and muscle strength in MG, with benefits seen as early as week 1.
-
MG symptoms may worsen in first trimester and postpartum period
Symptoms of myasthenia gravis (MG) may get worse during the first three months of pregnancy and in the months after the baby is born.
-
Telitacicept found safe and effective in older adults with MG
Older adults with MG who receive telitacicept as an add-on therapy experience improvements in symptoms and disease biomarkers, a study found.
-
Early targeted therapy improves outcomes in generalized MG, study suggests
A study found that adding targeted therapies within 24 months of a gMG diagnosis leads to better daily function and a higher quality of life.
-
Exercise and respiratory training may improve quality of life in myasthenia gravis
A new meta-analysis reveals structured physical activity and breathing training can improve muscle strength and quality of life in MG.
